Human pharmacology of 3,4-methylenedioxymethamphetamine ('Ecstasy'): Psychomotor performance and subjective effects

Journal of Clinical Psychopharmacology

Volumn 20, Issue 4, 2000, Pages 455-466

  Camí, Jordi ^b   Farré, MAGÍ ^c   Mas, Marta ^c   Roset, Pere N ^c   Poudevida, Sandra ^c   Mas, Anna ^c   San, Lluis ^a   De la Torre, Rafael ^c  

^a HOSPITAL DEL MAR   (Spain)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG ABUSE; DRUG EFFECT; DRUG SCREENING; DYSPHORIA; EUPHORIA; HUMAN; MALE; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; PSYCHOPHARMACOLOGY;

ADULT; AFFECT; CONFUSION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HALLUCINOGENS; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PSYCHOMOTOR PERFORMANCE; QUESTIONNAIRES;

EID: 0033941158     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200008000-00010     Document Type: Article

References (50)

1. Camí J, Farré M. Éxtasis, la droga de la ruta del bacalao. Med Clin (Barc) 1996;106:711-6.
2. Shulgin AT. History of MDMA. In: Peroutka SJ, ed. Ecstasy: the clinical, pharmacological and neurotoxicological effects of the drug MDMA. Boston: Kluwer Academic Publishers, 1990:1-20.
3. Steele TD, McCann UD, Ricaurte GA. 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"): pharmacology and toxicology in animals and humans. Addiction 1994;89:539-51.
4. Peroutka SJ. Incidence of recreational use of 3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy") on an undergraduate campus. N Engl J Med 1987;317:1542-3.
5. Liester MB, Grob CS, Bravo GL, Walsh RN. Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. J Nerv Ment Dis 1992;180:345-52.
6. Dowling GP, McDnough ET, Bost R. "Eve and ecstasy": a report of five deaths associated with the use of MDEA and MDMA. JAMA 1987;257:1615-7.
7. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 1992;340:384-7.
8. Ricaurte GA, DeLanney LE, Wiener SG, Irwin I, Langston JW. 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates. Brain Res 1988;474:359-63.
9. Green AR, Goodwin GM. Ecstasy and neurodegeneration. BMJ 1996;312:1493-4.
10. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 1998;352:1433-7.
11. Bolla KI, McCann UD, Ricaurte GA. Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology 1998;51:1532-7.
12. Downing J. The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 1986;18:335-40.
13. Greer B, Tolbert P. Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 1986;18:319-27.
14. Alvarez-Roldán A, Gamella JF, Sánchez J. Trends and patterns of Ecstasy use in Spain. In: Korf J, Riper H, eds. Illicit drug use in Europe. Amsterdam: Siswo, 1997:147-55.
15. Grob CS, Poland RE, Chang L, Ernst T. Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res 1996;73:103-7.
16. Vollenweider FX, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA ("Ecstasy") in MDMA-naïve healthy volunteers. Neuropsychopharmacology 1998;19:241-51.
17. Peroutka SJ, Newman H, Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1988;1:273-7.
18. Solowij N, Hall W, Lee N. Recreational MDMA use in Sydney: a profile of "Ecstasy" users and their experiences with the drug. Br J Addict 1992;87:1161-72.
19. Siegel RK. MDMA: non medical use and intoxication. J Psychoactive Drugs 1986;18:349-55.
20. Schmid B, Bircher J, Preisig R, Küpfer A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative o-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985;38:618-24.
21. Camí J, Mas M, Farré M, San L, Roset PN, Mas A, Poudevida S, de la Torre R. Pharmacological effects of MDMA in humans: dose-finding pilot study. In: Harris LS, ed. Problems of Drug Dependence 1997: Proceedings of the 59th Annual Scientific Meeting. The College on Problems of Drug Dependence, Inc., National Institute on Drug Abuse Research Monograph 178. Washington, DC: U.S. Government Printing Office, DHHS (NIH 98-4305), 1998:290.
22. Hindmarch I. Psychomotor function and psychoactive drugs. Br J Clin Pharmacol 1980;10:189-209.
23. Farré M, de la Torre R, Llorente M, Lamas X, Ugena B, Segura J, Camí J. Alcohol and cocaine interactions in humans. J Pharmacol Exp Ther 1993;266:1364-73.
24. Farré M, Terán MT, Camí J. A comparison of the acute behavioral effects of flunitrazepam and triazolam in healthy volunteers. Psychopharmacology (Berl) 1996;125:1-12.
25. Wechsler D. The measurement and appraisal of adult intelligence. Baltimore: Williams & Wilkins, 1958.
26. McLeod DR, Griffiths RR, Bigelow GE, Yingling J. An automated version of the digit symbol substitution test (DSST). Behav Res Methods Instrum 1982;14:463-6.
27. Hannington-Kiff JG. Measurement of recovery from outpatient general anesthesia with a simple ocular test. BMJ 1970;3:132-5.
28. Haertzen CA. An overview of the Addiction Center Research Inventory: an appendix and manual of scales. DHEW Publication No. (ADM) 79. Washington, DC: Department of Health, Education and Welfare, 1974.
29. Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1971;12:245-58.
30. Lamas X, Farré M, Llorente M, Camí J. Spanish version of the 49-item short version of the Addiction Research Center Inventory (ARCI). Drug Alcohol Depend 1994;35:203-9.
31. Preston KL, Jasinski DR, Testa M. Abuse potential and pharmacological comparison of tramadol and morphine. Drug Alcohol Depend 1991;27:7-17.
32. McNair DR, Lorr M, Droppleman LF. Profile of mood states. San Diego: Educational and Industrial Testing Service, 1971.
33. Johanson CE, Uhlenhuth EH. Drug preference and mood in humans: d-amphetamine. Psychopharmacology (Berl) 1980;71:275-9.
34. Hermle L, Spitzer M, Borchardt D, Kovar K, Gouzolis E. Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents? Neuropsychopharmacology 1993;8:171-6.
35. Weiss B, Laties VG. Enhancement of human performance by caffeine and amphetamines. Pharmacol Rev 1962;14:1-36.
36. Mattila ME, Mattila MJ, Nuotto E. Caffeine moderately antagonizes the effects of triazolam and zopiclone on the psychomotor performance of healthy subjects. Pharmacol Toxicol 1992;70:286-9.
37. Birnbaum MH. An esophoric shift associated with sustained fixation. Am J Optom Physiol Opt 1985;62:732-5.
38. Jasinski DR, Preston KL. Evaluation of mixtures of morphine and d-amphetamine for subjective and physiological effects. Drug Alcohol Depend 1986;17:1-13.
39. Cohen RS. Subjective reports on the effects of the MDMA ("Ecstasy") experience in humans. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:1137-45.
40. Davison D, Parrot AC. Ecstasy (MDMA) in recreational users: self-reported psychological and physiological effects. Hum Psychopharmacol 1997;12:221-6.
41. Fischman MW, Foltin RW. Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br J Addict 1991;86:1563-70.
42. Farré M, de la Torre R, González M, Terán MT, Roset PN, Menoyo E, Camí J. Cocaine and alcohol interactions in humans: neuroendocrine effects and cocaethylene metabolism. J Pharmacol Exp Ther 1997;283:164-76.
43. Lamas X, Farré M, Camí J. Acute effects of pentazocine, naloxone and morphine in opioid-dependent volunteers. J Pharmacol Exp Ther 1994;268:1485-92.
44. White SR, Obradovic T, Imel KM, Wheaton MJ. The effects of methylenedioxymethamphetamine (MDMA, "Ecstasy") on monoaminergic neurotransmission in the central nervous system. Prog Neurobiol 1996;49:455-79.
45. Cohen RS. Adverse symptomatology and suicide associated with the use of methylenedioxymethamphetamine (MDMA; "Ecstasy"). Biol Psychiatry 1996;39:819-20.
46. Pallanti S, Mazzi D. MDMA (Ecstasy) precipitation of panic disorder. Biol Psychiatry 1992;32:91-5.
47. McCann U, Slate SO, Ricaurte GA. Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"). Drug Saf 1996;15:107-15.
48. Mas M, Farré M, de la Torre R, Roset PN, Ortuño J, Segura J, Camí J. Cardiovascular and endocrine effects, and pharmacokinetics of MDMA in humans. J Pharmacol Exp Ther 1999;290:136-45.
49. Hegadoren KM, Martin-Iverson MT, Baker GB. Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine. Psychopharmacology (Berl) 1995;118:295-304.
50. Baker LE, Taylor MM. Assessment of the MDA and MDMA optical isomers in a stimulant-hallucinogen discrimination. Pharmacol Biochem Behav 1997;57:737-48.